Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma

21 May 2018

Abstract excerpt

BACKGROUND: PARP1 facilitates the recovery of DNA-damaged cells by recruiting DNA damage response molecules such as γH2AX and BRCA1/2, and plays a role in resistance to antitumor therapies. Therefore, PARP inhibition being evaluated as an anti-cancer therapy. However, there are limited studies regrading PARP inhibition in osteosarcoma. METHODS: We evaluated the expression of DNA damage response molecules in 35...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29784019
DOI: 10.1186/s13046-018-0772-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcomaPMID 29784019Read ↗

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic DrugsSemantic proximity Read ↗

AZD6738 overcomes acquired olaparib resistance in BRCA1 mutation triple-negative breast cancer through down-regulation of BRCA2 and RAD51.Semantic proximity Read ↗

The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.Semantic proximity Read ↗

Expression of Poly (Adenosine Diphosphate-Ribose) Polymerase and p53 in Epithelial Ovarian Cancer and Their Role in Prognosis and Disease OutcomeSemantic proximity Read ↗

Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian CancerSemantic proximity Read ↗

PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndromeSemantic proximity Read ↗

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeuticsSemantic proximity Read ↗

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedinSemantic proximity Read ↗

Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitorSemantic proximity Read ↗

PARP1 inhibition regulates tumor progression through modulation of RhoGDIα and vimentin in triple negative breast cancerSemantic proximity Read ↗

The combination of olaparib and camptothecin for effective radiosensitizationSemantic proximity Read ↗

Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.